Adam is Research Director, Biomedical Innovation and Regulatory Policy, at Duke-Margolis. In this role, he oversees Duke-Margolis’ portfolio of projects aimed at advancing regulatory science, promoting biomedical innovation, and ensuring the availability of safe and effective medical products.
Prior to joining Duke-Margolis, Adam served as the deputy director of the FDA’s Office of Program and Strategic Analysis, which serves as an “internal consultancy” for FDA’s Center for Drug Evaluation and Research, providing management consulting, policy analysis, process improvement, and advanced modeling and analytic methods to improve the center’s policy, decision-making, and operations. In this role, Adam managed analytical studies and major initiatives in a range of topics related to pharmaceutical regulation and drug safety, including studies on the impact of FDA’s efforts to ensure that drugs are used safely and the use of innovative health IT solutions to understand and address the opioid crisis and other critical public health needs.
B.S. in Policy Analysis and Management, Cornell University
Master of Science in Public Policy and Management, Carnegie Mellon University